Navigation Links
Naurex Announces Issuance Of New Patent For Novel Antidepressant GLYX-13
Date:7/30/2013

EVANSTON, Ill., July 30, 2013 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced issuance of a new U.S. patent for its lead compound, GLYX-13. The new patent, which covers methods of treating major depressive disorder, expires in 2030. GLYX-13 has demonstrated good safety, robust efficacy and rapid onset of effect within hours of a single dose in a Phase II trial.

"Issuance of this new patent extending protection for GLYX-13 is an important development for Naurex and adds significant value to our depression program," noted CEO Derek Small. "In addition, we are continuing to pursue additional patents for GLYX-13 to further fortify our patent portfolio for this promising new drug."

GLYX-13 is a selective NMDA receptor partial agonist, a new class of central nervous system-active compounds discovered by Naurex scientists. It is currently being assessed in a 400-subject Phase Il repeated dose clinical trial. Results from the initial Phase II trial showed that a single administration of GLYX-13 produced statistically significant reductions in depression scores in subjects who had failed treatment with current antidepressants. The reductions were evident within 24 hours and persisted for an average of seven days. In clinical studies to date, GLYX-13 has been well tolerated and has not produced any of the schizophrenia-like effects associated with other drugs that modulate the NMDA receptor.

GLYX-13 was developed based on the work of company founder, Joseph R. Moskal, PhD, and his colleagues at the Falk Center for Molecular Therapeutics at Northwestern University.

U.S. Patent No. 8,492,340 B2 issued on July 23, 2013, is assigned to Northwestern University and exclusively licensed to Naurex Inc.

About Naurex
Naurex Inc. is a clinical-stage private company developing novel therapies to address unmet needs in psychiatry and neurology based on a new mechanism of action for modulating the NMDA receptor (NMDAR). Lead product GLYX-13 has shown promising antidepressant activity with excellent safety in a Phase Ila clinical trial in subjects who had failed treatment with existing agents. GLYX-13 is currently in a Phase IIb repeated dose clinical trial as adjunctive therapy for major depressive disorder. Oral and IV formulations of Naurex's 2nd-generation compound, NRX-1074, are currently in Phase I clinical studies.  Naurex's patented novel chemistry classes represent a platform for the discovery and development of new CNS therapies and have generated a robust pipeline that includes 3rd- and 4th-generation NMDAR subtype-selective partial agonists with preclinical proof of concept in a number of CNS disorders. For more information, visit www.naurex.com.Contacts:

MediaNaurex Inc.

BLL Partners, LLCAshish Khanna

Barbara LindheimVice President, Corporate Development

(212) 584-2276(847) 871-0377

blindheim@bllbiopartners.comcorporate@naurex.com
'/>"/>

SOURCE Naurex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... , Dec. 3, 2016   Pairnomix, LLC, ... Medicine Alliance (PEPMA) recognized by the White House, today announced ... approach to the identification of candidate therapies for a patient ... SCN8A gene were presented at the 70 th ... Houston, TX , December 2-6, 2016.  ...
(Date:12/2/2016)... Research and Markets has announced the addition of the ... ... R&D Drug Pipeline Database: 1-Year Subscription ... provides 24/7 online access to information about more than 21,000 project ... drug candidates in research & development. Pre-established and ...
(Date:12/2/2016)... the ECG Cables And ECG Leadwires Market owing to the ... On the other hand, the Asia-Pacific ... during the forecast period. The market players namely, ... ( Ireland ), Koninklijke Philips N.V. ( ... China ), held major share of the ECG ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 04, 2016 , ... Are You Concerned About Mold In Your Home ... Indoor Air Quality Companies in VA, MD and DC, recently completed its application for ... new mold law in the district of Columbia is a good thing stated John ...
(Date:12/2/2016)... Calif. (PRWEB) , ... December 02, 2016 , ... On ... at the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who ... neoplasms (MPNs) by going above and beyond the standard of care, demonstrating leadership within ...
(Date:12/2/2016)... Portland, Maine (PRWEB) , ... December 02, 2016 , ... ... support group for caregivers of those affected by autism spectrum disorder (ASD) and other ... and Easter Seals Maine, will give parents and other caregivers the opportunity to share ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Hills, California, will be included in the 2016 “Guide to America’s Top Plastic ... based on the amalgamation of their education, experience, and professional associations. , ...
(Date:12/2/2016)... ... 02, 2016 , ... Universal Medical Systems, Inc. (UMS) the ... company to offer robotic imaging to veterinary medicine is sponsoring the appearance of ... the American Association of Equine Practitioners 62nd Annual Convention from December 4-6, 2016 ...
Breaking Medicine News(10 mins):